Our top pick for
Shineco Inc is a drug manufacturers-specialty & generic business based in the US. Shineco shares (TYHT) are listed on the NASDAQ and all prices are listed in US Dollars. Shineco employs 216 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.70|
|52-week range||$3.57 - $14.69|
|50-day moving average||$11.22|
|200-day moving average||$8.95|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.15|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-23)||N/A|
|1 month (2022-05-31)||N/A|
|3 months (2022-03-31)||N/A|
|6 months (2021-12-31)||N/A|
|1 year (2021-07-02)||2.92%|
|2 years (2020-07-02)||1,168.46%|
|3 years (2019-07-03)||915.00%|
|5 years (2017-07-03)||145.42%|
Valuing Shineco stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Shineco's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Shineco's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $906,949.
The EBITDA is a measure of a Shineco's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3 million|
|Gross profit TTM||$-287,694|
|Return on assets TTM||-15.55%|
|Return on equity TTM||-38.32%|
|Market capitalisation||$97.2 million|
TTM: trailing 12 months
We're not expecting Shineco to pay a dividend over the next 12 months.
Shineco's shares were split on a 1:9 basis on 16 August 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Shineco shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Shineco shares which in turn could have impacted Shineco's share price.
Over the last 12 months, Shineco's shares have ranged in value from as little as $3.57 up to $14.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Shineco's is 1.8466. This would suggest that Shineco's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Shineco, Inc. , together with its subsidiaries, produces, distributes, and sells health and well-being focused plant-based products in China. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers. The company also plants, processes, and distributes green and organic vegetables and fruits; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality. In addition, it offers logistics services for agricultural products. Further, the company develops, manufactures, and distributes specialized fabrics, textiles, health supplements, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum. The company sells its Chinese medicinal products and western medicines through wholesale customers; and its 13 Ankang retail pharmacies operating under the Sunsimiao Pharmacies name, as well as 66 pharmacies operated by third parties.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.